Dynorphin Increases Extracellular Levels of Excitatory Amino Acids in the Brain through a Non-opioid Mechanism
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Departments of Neurology and Pharmacology, Georgetown University School of Medicine, Washington, DC. 20007 Administration of dynorphin A-( l-1 7) (Dyn l-1 7), through a microdialysis probe stereotaxically placed into rat hippocampus, caused marked increases in the extracellular levels of glutamate and aspartate.
The degree and duration of elevation of these excitatory amino acids (EAA) induced by Dyn 1-17 were dose dependent but were not modified by the centrally active opioid receptor antagonist nalmefene. At comparable doses, Dyn 2-17, which is inactive at the opioid receptor, produced similar alterations in EAA as Dyn l-1 7, whereas Dyn l-8 caused significantly smaller changes of glutamate.
Dynorphin and EAAs have each been implicated as pathophysiological factors in brain or spinal cord injuries, with dynorphin's actions shown to involve both opioid and non-opioid components. The present observations indicate a direct potential linkage between dynorphin and excitotoxin mechanisms of CNS injury and provide further support for the concept that dynorphin's pathophysiologic effects may include non-opioid actions of this peptide.
Dynorphin A-( 1-17) (Dyn 1-17) is an endogenous opioid peptide that has been implicated in the pathophysiology of both traumatic brain injury (TBI) and spinal cord injury (SCI). Following SCI, dynorphin-like immunoreactive material accumulates at the trauma site in direct proportion to injury severity, whereas other endogenous opioids including methionine-enkephalin, leucine+nkephalin, or p-endorphin are unchanged (Faden et al., 1985) . Levels of dynorphin, but not those of other endogenous opioids, are also increased following TBI at sites showing the most severe neuropathological changes (McIntosh et al., 1987) . Administration of antiserum to dynorphin, but not antiserum to leucin-nkephalin, reduces posttraumatic neurological dysfunction after SC1 (Faden, 1990) ; in contrast, central administration of dynorphin exacerbates the consequences of TBI or SC1 Faden, 1990) . Consistent with its proposed pathophysiological role, intrathecal dynorphin administration causes biochemical changes within the spinal cord, diminished blood flow (Long et al., 1987) , motor deficits Received July 11, 1991; revised Sept. 11, 1991; accepted Sept. 18, 1991 (Faden and Jacobs, 1984; Herman and Goldstein, 1985; Long et al., 1988) and histological damage that simulate the consequences of spinal cord trauma (for review, see Bakshi et al., 1990) . Excitatory amino acids (EAA) have also been implicated as pathophysiological factors in SC1 and TBI through actions mediated by NMDA receptors. Extracellular levels of glutamate and aspartate increase markedly after CNS trauma Katayama et al., 1989; Nilsson et al., 1990; in proportion to injury severity; tissue levels of these EAA are also modified in response to trauma . NMDA, but not its enantiomer NMLA, worsens neurological dysfunction following SC1 (Faden and Simon, 1988) . Treatment with NMDA antagonists, including both competitive and noncompetitive blockers, limits behavioral deficits, biochemical and metabolic alterations, and anatomical changes after TBI (Hayes et al., 1988; Faden et al., 1989; Shapira et al., 1990) or SC1 (Faden and Simon, 1988; Gomez-Pinilla et al., 1989; Faden et al., 1990) .
That dynorphin-and excitotoxin-induced physiological changes may be linked was first suggested by Caudle and Isaac (1988) . This concept was supported and extended by others. Intrathecal dynorphin administration was shown to cause depletion of tissue levels of glutamate and aspartate (Bakshi et al., 1990) . Moreover, NMDA antagonists (including competitive, noncompetitive, or glycine site antagonists) were found to limit dynorphin-induced behavioral changes and mortality (Long et al., 1989; Bakshi and Faden, 1990a,b) .
The pathophysiological actions of dynorphin appear to be mediated by both opioid and non-opioid mechanisms (Faden, 1990) . Des-tyrosine-dynorphin (Dyn 2-17) is inactive at opioid receptors (Walker et al., 1982) yet simulates many of the pathophysiological consequences of Dyn 1-17. NMDA antagonists reduce neurological dysfunction after either Dyn 1-17 or Dyn 2-17 (Long et al., 1989; Bakshi and Faden, 1990a,b) . From such observations, it seems possible that dynorphin causes tissue damage, in part, through non-opioid mechanisms that include the release of EAA. To address this issue, microdialysis techniques have been used to determine whether dynorphin alters extracellular levels of glutamate or aspartate within the brain and whether such actions are opioid receptor mediated.
Materials and Methods
Male Spragu+Dawley rats (400 + 25 gm) were anesthetized with sodium pentobarbital(70 mg/kg body weight, i.p.). A microdialysis probe was implanted stereotaxically into hippocampus, as previously described for brain trauma studies . This site, which includes the CA2 and CA3 areas, shows delayed cell'loss (Cortez et al., 1989) as well as the release of EAA ) after fluid Rel ease of Excitatory Amino Acids percussion-induced trauma. It also contains dynorphin-immunoreactive fibers (Watson et al., 1982) and NMDA receptors (Greenamyre et al., 1984) . Perfusions were made with a CMA/lOO microinjection pump (Carnegie Medicin AB); the probe (Bioanalytical Systems) had an outside diameter of 0.5 mm and a molecular mass exclusion limit of approximately 20 kDa. Probes were tested before and following microdialysis against standard solutions of amino acids. Fifty minutes after probe placement, microdialysis was begun, using artificial cerebrospinal fluid as the perfusate with a flow rate of 2 rl/min. Samples, representing 10 min intervals, were analyzed for amino acids using high-performance liquid chromatography as previously described Faden et al., 1989) . Following two baseline measurements (20 min), dynorphin was infused beginning at t = 0 min through the microdialysis probe over 10 min at a rate of 2 pl/min; a preliminary experiment from our laboratory using 'H-dynorphin A-( 1 -17) showed that approximately 5% of the administered dynorphin was delivered to the brain, consistent with a previous report (Kendrick, 1989) . Groups included animals treated with Dyn 1-17 at doses of 10 nmol (n = 8), 30 nmol (n = 13), and 100 nmol (n = 9); Dyn 2-17 at a dose of 30 nmol (n = 11); Dyn l-8 at a dose of 30 nmol (n = 8); and nalmefene (100 fig) plus Dyn 1-17 at a dose of 100 nmol (n = 10). For the latter experiment, nalmefene was administered at a rate of 2 rl/min in artificial cerebrospinal fluid over 10 min, beginning at t = -30 min; as for the other experiments, dynorphin was administered beginning at t = 0 min over a 10 min period at a rate of 2 jd/min. Following the final microdialysis collection (t = 60 min), animals were killed through an intraperitoneal injection of T-61 (1 ml).
Results
Administration of Dyn 1-17 caused significant increases in extracellular levels of glutamate and asparate, which were related to dynorphin dose (Fig. 1) . Peak changes occurred at 20 min with maximal increases of 1340% for glutamate and 544% for aspartate at the highest dynorphin dose. Effects on other transmitter and nontransmitter amino acids are shown in Table 1 : glycine, GABA, serine, and taurine were also increased by Dyn l-l 7, although none showed a significant dose-dependent relationship.
Among these amino acids, glycine and serine may modulate NMDA receptor activity (Benavides et al., 1988; Snell et al., 1988; Thomson, 1989) . The alterations of the amino acids observed are qualitatively similar to those found after fluid percussion-induced TBI , impact-induced traumatic SC1 , or hypoxia-ischemia of brain (Hagberg et al., 1987) .
Two experiments were conducted to determine whether the dynorphin-induced increase of amino acids was opioid receptor . Changes in extracellular levels of the EAA glutamate and aspartate before and following administration of Dyn l-17 through a microdialysis probe placed in rat hippocampus. Average values and SE are plotted as a function of time of dynorphin injection, expressed as the concentration of amino acid in the dialysate. Dynorphin administration at each dose caused significant increases in glutamate and aspartate at 20 min (peak elevation) as compared to their respective baseline (pretreatment) values (see Table 1 ). Increases were significantly dose related: glutamate, r = 0.38, p = 0.04; aspartate, r = 0.4 1, p = 0.03, using regression ANOVA. whether the data are examined in terms of absoluie values& shown here or as percentage change from baseline (see Table 1 ). Alterations in glutamate, but not aspartate, after administration of Dyn l-17 were significantly higher than following Dyn l-8 (t test with Bonferroni correction, p < 0.05). Baseline values were similar across the groups and have been averaged here.
mediated. Dyn 2-17, which does not act at opioid receptors but is physiologically active (Walker et al., 1982) , produced elevations in glutamate and aspartate that were statistically indistinguishable from those of Dyn l-l 7 at similar doses (Fig. 2) . Consistent with this observation, administration of a relatively high dose of the opioid receptor antagonist nalmefene (Bakshi et al., 1990) failed to modify the effects of Dyn 1-17 on EAA release (Fig. 3) . Nalmefene, by itself, did not alter the basal levels of glutamate or aspartate.
To examine further the structure-activity relationship for dynorphin with regard to EAA changes, other animals received Dyn 1-8; this peptide, unlike Dyn 1-17, Dyn 2-17, Dyn 1-13, or Dyn 3-13, does not cause paralysis after intrathecal administration in rats (Przewlocki et al., 1983; Faden and Jacobs, 1984; Stevens and Yaksh, 1986) . Alterations in extracellular levels of glutamate or aspartate after Dyn l-8 were modest and were significantly less than those 6f Dyn 1-17 (Fig. 2) .
Discussion
Increasing evidence supports the concept that dynorphin-induced and excitotoxin-induced tissue injury may be closely linked. Intrathecal administration of dynorphin to rats, at doses that produce behavioral and histological changes, cause changes Table 1 .
in the tissue levels of glutamate and aspartate (Bakshi et al., 1990) . A variety of structurally different NMDA antagonists, with differing mechanisms of action, reduce neurological and histological abnormalities produced by dynorphin (Long et al., 1989; Bakshi and Faden, 1990a,b) . Consistent with these findings, the present data show that administration of dynorphin through a microdialysis probe placed in rat hippocampus causes a dose-related increase in the extracellular levels of glutamate and aspartate. Dynorphin-induced SC1 appears to be mediated, in part, through non-opioid mechanisms; Dyn 2-17 and Dyn 3-13, which are believed to be inactive at opioid receptors, cause changes in blood flow or motor function that are not modified by opioid receptor antagonists (Faden and Jacobs, 1984; Long et al., 1987 Long et al., , 1988 Faden, 1990) . The present findings show that Dyn l-l 7 and Dyn 2-17 cause indistinguishable increases of EAA, which are not modified by a centrally active opioid receptor antagonist, supporting a non-opioid mechanism of action. These observations are consistent with a growing body of evidence that dynorphin may have substantial physiological or pathophysiological actions that are not mediated by opioid receptors (Walker et al., 1982; Faden and Jacobs, 1984; Long et al., 1987 Long et al., , 1988 Faden, 1990) . There have been many reported relationships among opioids, opioid receptors, and EAA. Such relationships are complicated and may differ across various experimental models. Receptor binding studies using Dyn 1-13 demonstrated a direct interaction of this peptide with the NMDA receptor, where it may serve as an antagonist (Massardier and Hunt, 1989) . In support of this observation, high doses of dynorphin protected against NMDA-induced toxicity to cortical neurons in culture (Choi et al., 1989) . Other opioids, as well as their non-opioid enantiomers, also selectively attenuated NMDA neurotoxicity in the same cortical cell culture system, with the non-opioid dextroisomers being most active (Choi and Viseskul, 1988) . However, in hippocampal slice a variety of opioid agonists have been shown to increase synaptic excitability of dentate granule cells or CA1 pyramidal cells; dynorphin enhanced the excitability of the dentate granule cells, an action that was relatively insensitive to naloxone (Neumaier et al., 1988) . Moreover, a noncompetitive NMDA antagonist was found to inhibit morphine tolerance and dependence (Trujillo and Akil, 1991) . Glutamate and dynorphins can each be released from hippocampal mossy fiber synaptosomes (Terrian et al., 1988) , with both dynorphin-immunoreactive fibers and glutamate-binding sites found in the same hippocampal regions (Watson et al., 1982; Greenamyre et al., 1984) . In contrast to the results of the present study and some of the reports mentioned above, in other model systems the effects of endogenous opioids on EAA release appear to be mediated, at least in part, by opioid receptors. Thus, opioid receptor antagonists stereospecifically reduce the release of EAA following global cerebral ischemia and reperfusion (Graham et al., 1990b) and attenuate alterations of EAA after intrathecal dynorphin (Bakshi et al., 1990) .
The mechanism by which dynorphin may increase EAA is speculative. One possibility is that dynorphin reduces local tissue blood flow sufficiently to cause ischemia-mediated EAA release. Increased levels of glutamate and aspartate have been reported after global or focal brain ischemia (Benveniste, 1984; Globus, 1988; Graham et al., 1990a) . Dyn 1-13 and Dyn 3-13 caused marked decreases in spinal cord blood flow after intrathecal administration; changes produced by Dyn 1-13 and Dyn 3-13 are comparable and not modified by opioid receptor antagonists, indicating that this effect is not mediated by opioid receptors (Long et al., 1987) . It is also possible that dynorphin may affect release of EAA through a presynaptic mechanism. Presynaptic modulation of EAA release by NMDA receptors has been suggested from studies using cell culture or hippocampal slice techniques (McBean and Roberts, 1981; Crawford and Rosenberg, 1989; Lobner and Lipton, 1989; Morimoto and Koshland, 1990) . NMDA antagonists inhibit posttraumatic release of EAA in hippocampus, possibly through a presynaptic mechanism . Dynorphin administration also causes phospholipid hydrolysis (Bakshi et al., 1990) , which may cause a decline in free intracellular magnesium (Mg2+) (Vink et al., 1990) . Mg2+ has been shown to decrease after both brain and spinal cord trauma (Vink et al., 1988 , with the onset of the decline temporarily correlated with EAA release . Recent evidence indicates that intracellular Mg2+ can produce a voltage-dependent block of NMDA channels (Johnson and Asher, 1990) . Dynorphin-induced release of EAA may, therefore, also involve such a mechanism.
